Neuropathic pain: targeting the melatonin MT<sub>2</sub> receptor

  • Natasha Smith Sefako Makgatho Health Sciences University
  • Halima Ismail Sefako Makgatho Health Sciences University
  • Natalie Schellack Sefako Makgatho Health Sciences University
Keywords: melatonin, neuropathic pain, MT2 receptor, opioids, NSAIDs

Abstract

Neuropathic pain affects a large proportion of the population and reduces a person’s ability to perform optimally. In South Africa, there are a host of factors that hinder the correct diagnosis and treatment of neuropathic pain. Patients suffering from neuropathic pain are treated suboptimally with NSAIDS and opioids as first-line therapy. In 2012, a South African guideline on neuropathic pain was released, which stated that opioid therapy should be reserved for last-line treatment only. More recently, melatonin, commonly known as the neurohormone that regulates the circadian rhythm, has come to light as a therapeutic treatment option in the neuropathic pain setting. Early clinical trials showed a link between melatonin and chronic pain, which includes neuropathic pain. The MT2 receptor has also been specifically linked to the control of neuropathic pain and inflammation.

Author Biographies

Natasha Smith, Sefako Makgatho Health Sciences University
BPharm Academic Intern Department of Pharmacy Faculty of Health Sciences Sefako Makgatho Health Sciences University
Halima Ismail, Sefako Makgatho Health Sciences University
BPharm Academic Intern Department of Pharmacy Faculty of Health Sciences Sefako Makgatho Health Sciences University
Natalie Schellack, Sefako Makgatho Health Sciences University
BCur, BPharm, PhD Senior Lecturer Department of Pharmacy Faculty of Health Sciences Sefako Makgatho Health Sciences University
Section
Review Articles